- Home
- AQST vs NCV Comparison
AQST vs NCV Comparison
Compare AQST & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- NCV
- Stock Information
- Founded
- AQST 2004
- NCV 2003
- Country
- AQST United States
- NCV United States
- Employees
- AQST N/A
- NCV N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- NCV Finance Companies
- Sector
- AQST Health Care
- NCV Finance
- Exchange
- AQST Nasdaq
- NCV Nasdaq
- Market Cap
- AQST 285.4M
- NCV 326.2M
- IPO Year
- AQST 2018
- NCV N/A
- Fundamental
- Price
- AQST $3.10
- NCV $3.59
- Analyst Decision
- AQST Strong Buy
- NCV
- Analyst Count
- AQST 8
- NCV 0
- Target Price
- AQST $10.38
- NCV N/A
- AVG Volume (30 Days)
- AQST 1.5M
- NCV 405.1K
- Earning Date
- AQST 03-04-2025
- NCV 01-01-0001
- Dividend Yield
- AQST N/A
- NCV 12.48%
- EPS Growth
- AQST N/A
- NCV N/A
- EPS
- AQST N/A
- NCV N/A
- Revenue
- AQST $58,900,000.00
- NCV N/A
- Revenue This Year
- AQST $18.44
- NCV N/A
- Revenue Next Year
- AQST N/A
- NCV N/A
- P/E Ratio
- AQST N/A
- NCV N/A
- Revenue Growth
- AQST 22.56
- NCV N/A
- 52 Week Low
- AQST $2.24
- NCV $2.84
- 52 Week High
- AQST $6.23
- NCV $3.59
- Technical
- Relative Strength Index (RSI)
- AQST 34.77
- NCV 56.81
- Support Level
- AQST $2.96
- NCV $3.36
- Resistance Level
- AQST $3.30
- NCV $3.59
- Average True Range (ATR)
- AQST 0.21
- NCV 0.08
- MACD
- AQST 0.01
- NCV 0.01
- Stochastic Oscillator
- AQST 16.87
- NCV 97.83
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.